Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 Safety Study for the Treatment of COVID-19
NCT06489860Phase 2Withdrawn
- Sponsor
- DHA Coffee
- Start
- Jan 2025
- Primary completion
- Jan 2025
01
Overview
Phase 2, open-label, single-arm trial in coronavirus disease 2019 (COVID-19), human immunodeficiency virus infection (HIV) and malignant neoplasm, sponsored by DHA Coffee. Primary endpoint: SARS-CoV-2. Planned start Jan 2025; status: withdrawn.
02
Conditions
coronavirus disease 2019 (COVID-19)human immunodeficiency virus infection (HIV)malignant neoplasm
Beyond the preview
Go deeper on NCT06489860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489860.